Pfizer Hemophilia B Treatment Regimen Meets Endpoint

July 16, 2014 12:15 PM

17 0

Pfizer Inc. said a regimen for treating patients with hemophilia B met the primary endpoint of its Phase 3 trial.

The pharmaceutical giant said its Benefix coagulation factor IX regimen demonstrated a statistically significant reduction in bleeding rates for patients with moderately severe to severe hemophilia B, compared with rates for those receiving on-demand treatment with Benefix.

Read more

To category page